Literature DB >> 3265720

Type beta transforming growth factor and epidermal growth factor suppress the plasminogen activator activity in a human glioblastoma cell line.

E Helseth1, A Dalen, G Unsgaard, R Vik.   

Abstract

In the human glioblastoma cell line, T-MG1, plasminogen activator activity (PA-activity) was demonstrated by using the chromogenic substrate S-2251. Using monoclonal antibodies against human urokinase type PA (u-PA) and human tissue type PA (t-PA), only u-PA activity was found in T-MG1 cell extracts. The u-PA activity in T-MG1 cells was suppressed in a dose-dependent manner by B-TGF and EGF after 24 hours of exposure to these growth factors. Twenty units of B-TGF caused a decrease in PA-activity of 80%, while 10 ng/ml EGF gave a decrease in PA-activity of 60%. The suppressive effects of B-TGF and EGF were observed after 2 hours and 4 hours of incubation, respectively and sustained for at least 24 hours. The effects of B-TGF and EGF were not antienzymatic, but rather mediated through regulatory mechanisms. In view of the capacity of invasive growth of gliomas and the potential role of PA in invasive growth, the suppression of PA-activity in gliomas by B-TGF and EGF may be of importance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3265720     DOI: 10.1007/bf00163713

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  Epidermal growth factor, like phorbol esters, induces plasminogen activator in HeLa cells.

Authors:  L S Lee; I B Weinstein
Journal:  Nature       Date:  1978-08-17       Impact factor: 49.962

Review 2.  Transforming growth factors.

Authors:  A B Roberts; M B Sporn
Journal:  Cancer Surv       Date:  1985

3.  Use of chromogenic substrate S-2251 for determination of plasminogen activator in rat ovaries.

Authors:  H Shimada; T Mori; A Takada; Y Takada; Y Noda; I Takai; H Kohda; T Nishimura
Journal:  Thromb Haemost       Date:  1981-08-28       Impact factor: 5.249

4.  Molecular species of plasminogen activators secreted by normal and neoplastic human cells.

Authors:  E L Wilson; M L Becker; E G Hoal; E B Dowdle
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

5.  A new technique to register proliferation of clonogenic cells from brain tumors.

Authors:  G Unsgaard; B Larsen; A Dalen; R Vik; R Ringkjøb
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

6.  Antibodies to plasminogen activator inhibit human tumor metastasis.

Authors:  L Ossowski; E Reich
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

7.  Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells.

Authors:  T Masui; L M Wakefield; J F Lechner; M A LaVeck; M B Sporn; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

8.  Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts.

Authors:  L R Lund; A Riccio; P A Andreasen; L S Nielsen; P Kristensen; M Laiho; O Saksela; F Blasi; K Danø
Journal:  EMBO J       Date:  1987-05       Impact factor: 11.598

9.  Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification.

Authors:  L S Nielsen; J G Hansen; P A Andreasen; L Skriver; K Danø; J Zeuthen
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

10.  Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse.

Authors:  L I Larsson; L Skriver; L S Nielsen; J Grøndahl-Hansen; P Kristensen; K Danø
Journal:  J Cell Biol       Date:  1984-03       Impact factor: 10.539

View more
  3 in total

Review 1.  Angiogenic growth factors in neural embryogenesis and neoplasia.

Authors:  D Zagzag
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

Review 2.  Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.

Authors:  M Yamamoto; R Sawaya; S Mohanam; V H Rao; J M Bruner; G L Nicolson; K Ohshima; J S Rao
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  Industry progress report on neuro-oncology: a biotech update.

Authors:  Jessica S Haber; Matei A Banu; Ashley Ray; Kartik Kesavabhotla; John A Boockvar
Journal:  J Neurooncol       Date:  2013-02-20       Impact factor: 4.506

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.